作者:Scott E. Wolkenberg、Zhijian Zhao、David D. Wisnoski、William H. Leister、Julie O’Brien、Wei Lemaire、David L. Williams、Marlene A. Jacobson、Cyrille Sur、Gene G. Kinney、Doug J. Pettibone、Philip R. Tiller、Sheri Smith、Christopher Gibson、Bennett K. Ma、Stacey L. Polsky-Fisher、Craig W. Lindsley、George D. Hartman
DOI:10.1016/j.bmcl.2009.01.015
日期:2009.3
Glycine transporter 1 (GlyT1) represents a novel target for the treatment of schizophrenia via the potentiation of glutamatergic NMDA receptors. The discovery of 4,4-disubstituted piperidine inhibitors of GlyT1 which exhibit improved pharmacokinetic properties, including oral bioavailability, is discussed. (C) 2009 Elsevier Ltd. All rights reserved.